All Races

Table 1.24

Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites by Race/Ethnicity

Males

White

Black

|   | Rate <sup>b</sup><br>2014-2018   | APC <sup>c</sup><br>2009-2018  |   | Rate <sup>b</sup><br>2014-2018   | APC <sup>c</sup><br>2009-2018   |   | Rate <sup>b</sup><br>2014-2018   | APC°<br>2009-2018   |
|---|--|--|---|--|---|---|--|---|
| All Sites   | 489.2  | -1.6*  | All Sites   | 495.8  | -1.6*   | All Sites   | 518.9  | -2.5*   |
| Prostate  | 111.3  | -3.4*  | Prostate  | 104.1  | -3.8*   | Prostate  | 175.8  | -3.7*   |
| Lung and Bronchus   | 60.1   | -3.0*  | Lung and Bronchus   | 60.5   | -3.0*   | Lung and Bronchus   | 69.3   | -3.6*   |
| Colon and Rectum  | 43.2   | -2.0*  | Colon and Rectum  | 42.5   | -2.0*   | Colon and Rectum  | 49.9   | -3.0*   |
| Urinary Bladder   | 34.2   | -1.7*  | Urinary Bladder   | 37.5   | -1.7*   | Kidney and Renal Pelvis   | 24.4   | -0.3  |
| Melanoma of the Skin  | 29.3   | 0.9*   | Melanoma of the Skin  | 34.7   | 1.0*  | Urinary Bladder   | 19.2   | -1.6*   |
| Non-Hodgkin Lymphoma  | 23.7   | -0.8*  | Non-Hodgkin Lymphoma  | 24.9   | -0.8*   | Non-Hodgkin Lymphoma  | 17.7   | -1.0*   |
| Kidney and Renal Pelvis   | 22.6   | 0.5*   | Kidney and Renal Pelvis   |  | 0.5*  | Liver & IBDf  | 17.6   | 0.0   |
| Leukemia  | 18.3   | -0.7   | Leukemia  | 19.4   | -0.8  | Pancreas  | 17.0   | 0.0   |
| Oral Cavity and Pharynx   |  | 0.5*   | Oral Cavity and Pharynx   |  | 0.7*  | Myeloma   | 16.3   | -0.4  |
| Pancreas  | 15.0   | 0.6*   | Pancreas  | 15.2   | 0.7*  | Leukemia  | 13.9   | -0.5  |
| Liver & IBD <sup>f</sup>  | 13.8   | 0.7  | Liver & IBDf  | 12.5   | 1.1*  | Stomach   | 13.5   | -2.2*   |
| Stomach   | 9.7  | -1.6*  | Stomach   | 8.7  | -1.6*   | Oral Cavity and Pharynx   |  | -1.3*   |
| Myeloma   | 8.8  | 0.0  | Thyroid   | 8.5  | 0.6   | Larynx  | 7.0  | -3.8*   |
| Thyroid   | 8.0  | 0.8  | Brain and ONSf  | 8.3  | -0.5*   | Esophagus   | 5.8  | -4.1*   |
| Brain and ONSf  | 7.6  | -0.5*  | Myeloma   | 8.2  | 0.0   | Brain and ONSf  | 4.6  | -0.5  |
|   |  |  | •   |  |   |   |  |   |
| Asian/Pacific Islander  |  |  | American Indian/Alaska Native <sup>d</sup>  |  |   | Hispanic <sup>e</sup>   |  |   |
| Asian/Pacific   | Islander   |  | American Indian/  | Alaska Nat:  | ive <sup>d</sup>  | Hispan  | ic <sup>e</sup>  |   |
| Asian/Pacific   | Rateb  | APC <sup>c</sup>   | American Indian/  | Rateb  | APC°  | Hispan  | Rateb  | APC <sup>c</sup>  |
|   | Rate <sup>b</sup><br>2014-2018   | 2009-2018  |   | Rate <sup>b</sup><br>2014-2018   | APC°<br>2009-2018   |   | Rate <sup>b</sup><br>2014-2018   | 2009-2018   |
| All Sites   | Rate <sup>b</sup><br>2014-2018<br>309.1  | <u>2009-2018</u><br>-1.8*  | All Sites   | Rate <sup>b</sup><br>2014-2018<br>326.7  | APC <sup>c</sup><br>2009-2018<br>-1.6*                                    | All Sites   | Rate <sup>b</sup><br>2014-2018<br>375.3  | <u>2009-2018</u><br>-2.2*   |
| All Sites<br>Prostate   | Rate <sup>b</sup><br>2014-2018<br>309.1<br>57.7  | -1.8*<br>-3.8*   | All Sites<br>Prostate   | Rate <sup>b</sup><br>2014-2018<br>326.7<br>53.1  | APC°<br>2009-2018<br>-1.6*<br>-5.4*                                       | All Sites<br>Prostate   | Rate <sup>b</sup><br>2014-2018<br>375.3<br>90.9  | 2009-2018<br>-2.2*<br>-5.0*   |
| All Sites<br>Prostate<br>Lung and Bronchus  | Rate <sup>b</sup> 2014-2018 309.1 57.7 45.0  | 2009-2018<br>-1.8*<br>-3.8*<br>-1.9*   | All Sites<br>Prostate<br>Lung and Bronchus  | Rate <sup>b</sup> 2014-2018 326.7 53.1 40.9  | APC° 2009-2018 -1.6* -5.4* -3.4*  | All Sites Prostate Colon and Rectum   | Rate <sup>b</sup><br>2014-2018<br>375.3<br>90.9<br>39.5  | 2009-2018<br>-2.2*<br>-5.0*<br>-2.0*  |
| All Sites Prostate Lung and Bronchus Colon and Rectum   | Rate <sup>b</sup> 2014-2018 309.1 57.7 45.0 37.1   | -1.8*<br>-3.8*<br>-1.9*<br>-2.3*   | All Sites Prostate Lung and Bronchus Colon and Rectum   | Rate <sup>b</sup> 2014-2018 326.7 53.1 40.9 39.6   | APC° 2009-2018 -1.6* -5.4* -3.4* -3.5*                                    | All Sites Prostate Colon and Rectum Lung and Bronchus   | Rate <sup>b</sup> 2014-2018 375.3 90.9 39.5 34.4   | 2009-2018<br>-2.2*<br>-5.0*<br>-2.0*<br>-2.9*   |
| All Sites Prostate Lung and Bronchus Colon and Rectum Liver & IBD <sup>f</sup>  | Rate <sup>b</sup> 2014-2018 309.1 57.7 45.0 37.1 19.4  | -1.8*<br>-1.8*<br>-3.8*<br>-1.9*<br>-2.3*<br>-2.6*   | All Sites Prostate Lung and Bronchus Colon and Rectum Kidney and Renal Pelvis   | Rate <sup>b</sup> 2014-2018 326.7 53.1 40.9 39.6 24.2  | APC° 2009-2018 -1.6* -5.4* -3.4* -3.5* 0.9                                | All Sites Prostate Colon and Rectum Lung and Bronchus Kidney and Renal Pelvis   | Rate <sup>b</sup> 2014-2018 375.3 90.9 39.5 34.4 21.6  | - 2009-2018<br>-2.2*<br>-5.0*<br>-2.0*<br>-2.9*<br>1.2*   |
| All Sites Prostate Lung and Bronchus Colon and Rectum Liver & IBD <sup>f</sup> Non-Hodgkin Lymphoma   | Rate <sup>b</sup> 2014-2018 309.1 57.7 45.0 37.1 19.4 16.5                                       | -1.8*<br>-1.8*<br>-3.8*<br>-1.9*<br>-2.3*<br>-2.6*<br>-0.4   | All Sites Prostate Lung and Bronchus Colon and Rectum Kidney and Renal Pelvis Liver & IBD <sup>f</sup>  | Rate <sup>b</sup> 2014-2018 326.7 53.1 40.9 39.6 24.2 21.7                                       | APC°  | All Sites Prostate Colon and Rectum Lung and Bronchus Kidney and Renal Pelvis Non-Hodgkin Lymphoma  | Rate <sup>b</sup> 2014-2018 375.3 90.9 39.5 34.4 21.6 20.7                                       | 2009-2018<br>-2.2*<br>-5.0*<br>-2.0*<br>-2.9*<br>1.2*<br>-0.8   |
| All Sites Prostate Lung and Bronchus Colon and Rectum Liver & IBD <sup>f</sup>  | Rate <sup>b</sup> 2014-2018 309.1 57.7 45.0 37.1 19.4 16.5 15.6                                  | -1.8*<br>-1.8*<br>-3.8*<br>-1.9*<br>-2.3*<br>-2.6*<br>-0.4<br>-0.8   | All Sites Prostate Lung and Bronchus Colon and Rectum Kidney and Renal Pelvis   | Rate <sup>b</sup> 2014-2018 326.7 53.1 40.9 39.6 24.2 21.7 17.0                                  | APC° 2009-2018 -1.6* -5.4* -3.4* -3.5* 0.9 1.5                            | All Sites Prostate Colon and Rectum Lung and Bronchus Kidney and Renal Pelvis Non-Hodgkin Lymphoma Liver & IBD <sup>f</sup>   | Rate <sup>b</sup> 2014-2018 375.3 90.9 39.5 34.4 21.6 20.7 20.4                                  | 2009-2018<br>-2.2*<br>-5.0*<br>-2.0*<br>-2.9*<br>1.2*<br>-0.8<br>-0.6   |
| All Sites Prostate Lung and Bronchus Colon and Rectum Liver & IBD <sup>f</sup> Non-Hodgkin Lymphoma Urinary Bladder Stomach   | Rate <sup>b</sup> 2014-2018 309.1 57.7 45.0 37.1 19.4 16.5 15.6 13.4                             | -1.8* -1.9* -2.3* -2.6* -0.4 -0.8 -3.1*  | All Sites Prostate Lung and Bronchus Colon and Rectum Kidney and Renal Pelvis Liver & IBD <sup>f</sup> Urinary Bladder Pancreas   | Rate <sup>b</sup> 2014-2018 326.7 53.1 40.9 39.6 24.2 21.7 17.0 13.4                             | APC° - 2009-2018 -1.6* -5.4* -3.4* -3.5* 0.9 1.5 1.5 2.5                  | All Sites Prostate Colon and Rectum Lung and Bronchus Kidney and Renal Pelvis Non-Hodgkin Lymphoma Liver & IBD <sup>f</sup> Urinary Bladder   | Rate <sup>b</sup> 2014-2018 375.3 90.9 39.5 34.4 21.6 20.7 20.4 19.1                             | 2009-2018<br>-2.2*<br>-5.0*<br>-2.9*<br>1.2*<br>-0.8<br>-0.6<br>-1.8*   |
| All Sites Prostate Lung and Bronchus Colon and Rectum Liver & IBD <sup>f</sup> Non-Hodgkin Lymphoma Urinary Bladder   | Rate <sup>b</sup> 2014-2018 309.1 57.7 45.0 37.1 19.4 16.5 15.6 13.4 12.3                        | -1.8* -3.8* -1.9* -2.3* -2.6* -0.4 -0.8 -3.1* 0.4  | All Sites Prostate Lung and Bronchus Colon and Rectum Kidney and Renal Pelvis Liver & IBD <sup>f</sup> Urinary Bladder Pancreas Oral Cavity and Pharynx   | Rate <sup>b</sup> 2014-2018 326.7 53.1 40.9 39.6 24.2 21.7 17.0 13.4 12.2                        | APC° - 2009-2018 -1.6* -5.4* -3.4* -3.5* 0.9 1.5 1.5 2.5 -0.5             | All Sites Prostate Colon and Rectum Lung and Bronchus Kidney and Renal Pelvis Non-Hodgkin Lymphoma Liver & IBD <sup>f</sup> Urinary Bladder Leukemia  | Rate <sup>b</sup> 2014-2018 375.3 90.9 39.5 34.4 21.6 20.7 20.4 19.1 13.2                        | -2.09-2018<br>-2.2*<br>-5.0*<br>-2.9*<br>1.2*<br>-0.8<br>-0.6<br>-1.8*<br>-0.9  |
| All Sites Prostate Lung and Bronchus Colon and Rectum Liver & IBD <sup>f</sup> Non-Hodgkin Lymphoma Urinary Bladder Stomach   | Rate <sup>b</sup> 2014-2018 309.1 57.7 45.0 37.1 19.4 16.5 15.6 13.4                             | -1.8* -3.8* -1.9* -2.3* -2.6* -0.4 -0.8 -3.1* 0.4 0.5  | All Sites Prostate Lung and Bronchus Colon and Rectum Kidney and Renal Pelvis Liver & IBD <sup>f</sup> Urinary Bladder Pancreas   | Rate <sup>b</sup> 2014-2018 326.7 53.1 40.9 39.6 24.2 21.7 17.0 13.4                             | APC° - 2009-2018 -1.6* -5.4* -3.4* -3.5* 0.9 1.5 1.5 2.5                  | All Sites Prostate Colon and Rectum Lung and Bronchus Kidney and Renal Pelvis Non-Hodgkin Lymphoma Liver & IBD <sup>f</sup> Urinary Bladder   | Rate <sup>b</sup> 2014-2018 375.3 90.9 39.5 34.4 21.6 20.7 20.4 19.1                             | -2.09-2018<br>-2.2*<br>-5.0*<br>-2.9*<br>1.2*<br>-0.8<br>-0.6<br>-1.8*<br>-0.9<br>-2.0*                                 |
| All Sites Prostate Lung and Bronchus Colon and Rectum Liver & IBD <sup>f</sup> Non-Hodgkin Lymphoma Urinary Bladder Stomach Kidney and Renal Pelvis Oral Cavity and Pharynx Pancreas                          | Rate <sup>b</sup> 2014-2018 309.1 57.7 45.0 37.1 19.4 16.5 15.6 13.4 12.3 12.1 10.9              | - 2009-2018<br>-1.8*<br>-3.8*<br>-1.9*<br>-2.3*<br>-2.6*<br>-0.4<br>-0.8<br>-3.1*<br>0.4<br>0.5<br>0.4                         | All Sites Prostate Lung and Bronchus Colon and Rectum Kidney and Renal Pelvis Liver & IBD <sup>f</sup> Urinary Bladder Pancreas Oral Cavity and Pharynx Non-Hodgkin Lymphoma Leukemia                 | Rate <sup>b</sup> 2014-2018 326.7 53.1 40.9 39.6 24.2 21.7 17.0 13.4 12.2 11.8 11.7              | APC° 2009-2018 -1.6* -5.4* -3.4* -3.5* 0.9 1.5 1.5 2.5 -0.5 -2.7 2.9      | All Sites Prostate Colon and Rectum Lung and Bronchus Kidney and Renal Pelvis Non-Hodgkin Lymphoma Liver & IBD <sup>f</sup> Urinary Bladder Leukemia Stomach Pancreas   | Rate <sup>b</sup> 2014-2018 375.3 90.9 39.5 34.4 21.6 20.7 20.4 19.1 13.2 13.1 12.8              | -2009-2018<br>-2.2*<br>-5.0*<br>-2.9*<br>1.2*<br>-0.8<br>-0.6<br>-1.8*<br>-0.9<br>-2.0*                                 |
| All Sites Prostate Lung and Bronchus Colon and Rectum Liver & IBD <sup>f</sup> Non-Hodgkin Lymphoma Urinary Bladder Stomach Kidney and Renal Pelvis Oral Cavity and Pharynx                                   | Rate <sup>b</sup> 2014-2018 309.1 57.7 45.0 37.1 19.4 16.5 15.6 13.4 12.3 12.1 10.9 10.3         | - 2009-2018<br>-1.8*<br>-3.8*<br>-1.9*<br>-2.6*<br>-0.4<br>-0.8<br>-3.1*<br>0.4<br>0.5<br>0.4<br>-0.4                          | All Sites Prostate Lung and Bronchus Colon and Rectum Kidney and Renal Pelvis Liver & IBD <sup>f</sup> Urinary Bladder Pancreas Oral Cavity and Pharynx Non-Hodgkin Lymphoma                          | Rate <sup>b</sup> 2014-2018 326.7 53.1 40.9 39.6 24.2 21.7 17.0 13.4 12.2 11.8 11.7 10.1         | APC° 2009-2018 -1.6* -5.4* -3.4* -3.5* 0.9 1.5 1.5 2.5 -0.5 -2.7          | All Sites Prostate Colon and Rectum Lung and Bronchus Kidney and Renal Pelvis Non-Hodgkin Lymphoma Liver & IBD <sup>f</sup> Urinary Bladder Leukemia Stomach  | Rate <sup>b</sup> 2014-2018 375.3 90.9 39.5 34.4 21.6 20.7 20.4 19.1 13.2 13.1 12.8 10.3         | -2.09-2018<br>-2.2*<br>-5.0*<br>-2.9*<br>1.2*<br>-0.8<br>-0.6<br>-1.8*<br>-0.9<br>-2.0*<br>0.1<br>-1.2                  |
| All Sites Prostate Lung and Bronchus Colon and Rectum Liver & IBD <sup>f</sup> Non-Hodgkin Lymphoma Urinary Bladder Stomach Kidney and Renal Pelvis Oral Cavity and Pharynx Pancreas Leukemia Thyroid         | Rate <sup>b</sup> 2014-2018 309.1 57.7 45.0 37.1 19.4 16.5 15.6 13.4 12.3 12.1 10.9 10.3 7.9     | - 2009-2018<br>-1.8*<br>-3.8*<br>-1.9*<br>-2.3*<br>-2.6*<br>-0.4<br>-0.8<br>-3.1*<br>0.4<br>0.5<br>0.4<br>-0.4<br>1.6*         | All Sites Prostate Lung and Bronchus Colon and Rectum Kidney and Renal Pelvis Liver & IBD <sup>f</sup> Urinary Bladder Pancreas Oral Cavity and Pharynx Non-Hodgkin Lymphoma Leukemia Stomach Myeloma | Rate <sup>b</sup> 2014-2018 326.7 53.1 40.9 39.6 24.2 21.7 17.0 13.4 12.2 11.8 11.7 10.1 6.8     | APC° 2009-2018 -1.6* -5.4* -3.4* -3.5* 0.9 1.5 1.5 2.5 -0.5 -2.7 2.9 -4.0 | All Sites Prostate Colon and Rectum Lung and Bronchus Kidney and Renal Pelvis Non-Hodgkin Lymphoma Liver & IBD <sup>f</sup> Urinary Bladder Leukemia Stomach Pancreas Oral Cavity and Pharynx Myeloma         | Rate <sup>b</sup> 2014-2018 375.3 90.9 39.5 34.4 21.6 20.7 20.4 19.1 13.2 13.1 12.8 10.3 8.2     | - 2009-2018<br>-2.2*<br>-5.0*<br>-2.9*<br>1.2*<br>-0.8<br>-0.6<br>-1.8*<br>-0.9<br>-2.0*<br>0.1<br>-1.2<br>-0.7         |
| All Sites Prostate Lung and Bronchus Colon and Rectum Liver & IBD <sup>f</sup> Non-Hodgkin Lymphoma Urinary Bladder Stomach Kidney and Renal Pelvis Oral Cavity and Pharynx Pancreas Leukemia Thyroid Myeloma | Rate <sup>b</sup> 2014-2018 309.1 57.7 45.0 37.1 19.4 16.5 15.6 13.4 12.3 12.1 10.9 10.3 7.9 4.8 | - 2009-2018<br>-1.8*<br>-3.8*<br>-1.9*<br>-2.3*<br>-2.6*<br>-0.4<br>-0.8<br>-3.1*<br>0.4<br>0.5<br>0.4<br>-0.4<br>1.6*<br>-1.2 | All Sites Prostate Lung and Bronchus Colon and Rectum Kidney and Renal Pelvis Liver & IBD <sup>f</sup> Urinary Bladder Pancreas Oral Cavity and Pharynx Non-Hodgkin Lymphoma Leukemia Stomach         | Rate <sup>b</sup> 2014-2018 326.7 53.1 40.9 39.6 24.2 21.7 17.0 13.4 12.2 11.8 11.7 10.1 6.8 6.4 | APC° 2009-2018 -1.6* -5.4* -3.4* -3.5* 0.9 1.5 1.5 2.5 -0.5 -2.7 2.9 -4.0 | All Sites Prostate Colon and Rectum Lung and Bronchus Kidney and Renal Pelvis Non-Hodgkin Lymphoma Liver & IBD <sup>f</sup> Urinary Bladder Leukemia Stomach Pancreas Oral Cavity and Pharynx Myeloma Thyroid | Rate <sup>b</sup> 2014-2018 375.3 90.9 39.5 34.4 21.6 20.7 20.4 19.1 13.2 13.1 12.8 10.3 8.2 6.0 | - 2009-2018<br>-2.2*<br>-5.0*<br>-2.9*<br>1.2*<br>-0.8<br>-0.6<br>-1.8*<br>-0.9<br>-2.0*<br>0.1<br>-1.2<br>-0.7<br>2.2* |
| All Sites Prostate Lung and Bronchus Colon and Rectum Liver & IBD <sup>f</sup> Non-Hodgkin Lymphoma Urinary Bladder Stomach Kidney and Renal Pelvis Oral Cavity and Pharynx Pancreas Leukemia Thyroid         | Rate <sup>b</sup> 2014-2018 309.1 57.7 45.0 37.1 19.4 16.5 15.6 13.4 12.3 12.1 10.9 10.3 7.9     | - 2009-2018<br>-1.8*<br>-3.8*<br>-1.9*<br>-2.3*<br>-2.6*<br>-0.4<br>-0.8<br>-3.1*<br>0.4<br>0.5<br>0.4<br>-0.4<br>1.6*         | All Sites Prostate Lung and Bronchus Colon and Rectum Kidney and Renal Pelvis Liver & IBD <sup>f</sup> Urinary Bladder Pancreas Oral Cavity and Pharynx Non-Hodgkin Lymphoma Leukemia Stomach Myeloma | Rate <sup>b</sup> 2014-2018 326.7 53.1 40.9 39.6 24.2 21.7 17.0 13.4 12.2 11.8 11.7 10.1 6.8     | APC° 2009-2018 -1.6* -5.4* -3.4* -3.5* 0.9 1.5 1.5 2.5 -0.5 -2.7 2.9 -4.0 | All Sites Prostate Colon and Rectum Lung and Bronchus Kidney and Renal Pelvis Non-Hodgkin Lymphoma Liver & IBD <sup>f</sup> Urinary Bladder Leukemia Stomach Pancreas Oral Cavity and Pharynx Myeloma         | Rate <sup>b</sup> 2014-2018 375.3 90.9 39.5 34.4 21.6 20.7 20.4 19.1 13.2 13.1 12.8 10.3 8.2     | - 2009-2018<br>-2.2*<br>-5.0*<br>-2.9*<br>1.2*<br>-0.8<br>-0.6<br>-1.8*<br>-0.9<br>-2.0*<br>0.1<br>-1.2<br>-0.7         |

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

- a Top 15 cancer sites selected based on 2014-2018 age-adjusted rates for the race/ethnic group.
- Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups Census P25-1130).
- The APC is the Annual Percent Change over the time interval.
- Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups Census P25-1130).
- d Rates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.
- Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.
- IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.
- The APC is significantly different from zero (p<.05).
- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.